FDA Set to Decide on a New Non-Stimulant ADHD Drug for Children and Adults on July 24
FDA decides on centanafadine July 24, 2026 — a first-in-class non-stimulant ADHD drug for children, adolescents, and adults. Four Phase 3 trials support the application.
Read the full articleYou might also wanna read
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT
CME | Stimulants & Strategy: Integrating ADHD Treatments Into Daily Practice
In this episode of CME on the go, recorded live at FMX in Anaheim, our hosts discuss the complexities of ADHD treatment. They cover initial
Can ADHD contribute to divorce? How ADHD symptoms affect marriage, child custody, and divorce
More American adults than ever have an attention-deficit/hyperactivity disorder diagnosis. A 2024 Centers for Disease Control and Prevention
FDA's Psychedelic Guidance; Mass Shootings and Car Crashes; ADHD Drug Misuse Down
(MedPage Today) -- The FDA finalized clinical guidance for psychedelic drug developers and scheduled a public hearing for September to discu
Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Current Evidence and Clinical Practice
Research over the past decade have refined our understanding of ADHD epidemiology, neurobiology, diagnosis, and treatment, with growing emph
Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Current Evidence and Clinical Practice
Research over the past decade have refined our understanding of ADHD epidemiology, neurobiology, diagnosis, and treatment, with growing emph
CME | Focus Forward: Navigating ADHD Across the Lifespan
The CME on the Go series of the Inside Family Medicine podcast lets you earn up to 0.5 CME credits per episode — join the hosts as they dive
Comments
Sign in to join the conversation.
No comments yet. Be the first.